ACCESS AND FLOW

TIMELY 90th percentile ED length of stay	Last Year's Performance (LY)		Current Year's Performance (CY)		↓ Lower is bettero Target
			8.5		
	2023/24	Target	2024/25	Target	CY
TIMELY	Last Year's Perform	nance (LY)	nce (LY) Current Year's Performance (C		\downarrow Lower is better
90th percentile ambulance offload time					• Target
			51.0		
	2023/24	Target	2024/25	Target	CY
TIMELY	Last Year's Perform	nance (LY)	Current Year's Per	ormance (CY)	\downarrow Lower is better
90th percentile emergency department wait					• Target
time to inpatient bed			22.4	22.0	
	2023/24	Target	2024/25	Target	CY
TIMELY	Last Year's Perform	nance (LY)	Current Year's Perf	ormance (CY)	\downarrow Lower is better
Percent of patients who visited the ED and					 Target
left without being seen by a physician			6.6		
	2023/24	Target	2024/25	Target	CY

2 EXECUTIVE SUMMARY QIP 2024/25

TIMELY	Last Year's Performance (LY)		Current Year's Per		
Reporting the number of new coordinated care plans(CCP's) created for CHF and COPD patients in the CHIS HPG system to be			CB	100.0	∘ Target o
accessed/utilized by COHT partners.	2023/24	Target	2024/25	Target	
Collaborators: Couchiching FHT, Couchiching OHT					
EFFICIENT	Last Year's Perform	ance (LY)	Current Year's Per	formance (CY)	↑ Higher is better • Target
Alternate level of care (ALC) throughput ratio			1.0		
	2023/24	Target	2024/25	Target	CY

EQUITABLE	Last Year's Performance (LY) Current Year's Performance (CY)		\downarrow Lower is better		
Average ED wait time to physician initial assessment (PIA) for individuals with sickle cell disease (CTAS 1 or 2)			X		∘ Target
	2023/24	Target	2024/25	Target	
EQUITABLE	Last Year's Perform	nance (LY)	Current Year's Per	formance (CY)	↓ Lower is better
Rate of ED 30-day repeat visits for					• Target
ndividuals with sickle cell disease			X		
	2023/24	Target	2024/25	Target	
QUITABLE	Last Year's Perform	nance (LY)	Current Year's Per	formance (CY)	
Percentage of ED visits for individuals with sickle cell disease triaged with high severity (CTAS 1 or 2)			X		∘ Target
	2023/24	Target	2024/25	Target	

4 EXECUTIVE SUMMARY QIP 2024/25

EQUITABLE Percentage of staff (executive-level,	Last Year's Performance (LY)		Current Year's Per	• Target	
management, or all) who have completed relevant equity, diversity, inclusion, and anti- racism education	2023/24	Target	2024/25	Target	
EQUITABLE	Last Year's Perform	nance (LY)	Current Year's Per	formanco (CV)	
		· · /		Tormance (CT)	
Percentage of staff (executive-level, senior management, board) who have completed relevant equity, diversity, inclusion, and anti-			СВ	100.0	∘ Target o

EXPERIENCE

Last Year's Performance (LY)		Current Year's Per	\uparrow Higher is better	
2023/24	Target	2024/25	Target	• Target
Last Year's Perform	nance (LY)	Current Year's Per	formance (CY)	
		СВ	75.0	• Target o
2023/24	Target	2024/25	Target	
	2023/24 Last Year's Perform	2023/24 Target Last Year's Performance (LY)	2023/24 Target 2024/25 Last Year's Performance (LY) Current Year's Performance CB	2023/24Target2024/25TargetLast Year's Performance (LY)Current Year's Performance (CY)CB75.0

					SAFET
SAFE	Last Year's Performance (LY)		Current Year's Performance (CY)		
Rate of delirium onset during hospitalization			1.2		• Target
	2023/24	Target	2024/25	Target	CY
SAFE	Last Year's Perforn	nance (LY)	Current Year's Perf	ormance (CY)	
Rate of workplace violence incidents resulting in lost time injury					∘ Target
	2023/24	Target	2024/25	Target	
SAFE	Last Year's Perforn	nance (LY)	Current Year's Perf	ormance (CY)	
The number of lost time incidents due to workplace violence (WPV) injury.			4.0	5.0	• Target
	2023/24	Target	2024/25	Target	CY

• • • • • • • • •

7 EXECUTIVE SUMMARY QIP 2024/25

EFFECTIVE	Last Year's Perform	nance (LY)	Current Year's Perfo	ormance (CY)	1 Higher is better
Medication reconciliation at discharge: Total number of discharged patients for whom a Best Possible Medication Discharge Plan was	83 7	83.0			• Target
created as a proportion the total number of patients discharged.	2023/24	Target	2024/25	Target	LY